Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment.

about

Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth

P2860

Q57176933-405666CD-138B-4E29-A7E7-9D8D9E6342B5 Q58759078-BF9738BE-FEC6-4E20-BBF7-2CB72A3F5861

P2860

Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment.

Item

http://www.wikidata.org/entity/Q49787173

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Epstein-Barr Virus as a Promis ...... haryngeal Carcinoma Treatment.

@en

Epstein-Barr Virus as a Promis ...... haryngeal Carcinoma Treatment.

@nl

type

Item

label

Epstein-Barr Virus as a Promis ...... haryngeal Carcinoma Treatment.

@en

Epstein-Barr Virus as a Promis ...... haryngeal Carcinoma Treatment.

@nl

prefLabel

Epstein-Barr Virus as a Promis ...... haryngeal Carcinoma Treatment.

@en

Epstein-Barr Virus as a Promis ...... haryngeal Carcinoma Treatment.

@nl

P1476

Epstein-Barr Virus as a Promis ...... pharyngeal Carcinoma Treatment

@en

P2093

Hooi-Yeen Yap

http://www.w3.org/2001/XMLSchema#string

Suat-Cheng Peh

http://www.w3.org/2001/XMLSchema#string

P2860

Toxicities of Immunotherapy for the Practitioner

Regulation of the latent-lytic switch in Epstein-Barr virus

Co-infection of Epstein-Barr virus and human papillomavirus in human tumorigenesis

Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis

Epstein-Barr virus latent genes

Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies

Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies.

Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma.

Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A.

Immunotherapy in head and neck cancer: aiming at EXTREME precision.

P304

7349268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/7349268

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

Sin-Yeang Teow

P577

2017-12-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29464124

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

Epstein–Barr virus

P932

5804410

http://www.w3.org/2001/XMLSchema#string

Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment.

about

P2860

P2860

Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932